United StatesIMTX▲
Moderna's Stock Surge Opens Door for Four Strategic Acquisition Targets
Moderna's stock surged 176.9% to $174.38 on August 19, 2026, lifting its market capitalization to roughly $69.6 billion and strengthening its acquisition currency. The company still guides to a year-end 2026 cash and investments balance of between $4.7 billion and $5.2 billion, plus an undrawn $0.9 billion credit facility, and the $950 million Arbutus/Genevant settlement is largely resolved. CEO Stéphane Bancel said Moderna is preparing for "the growth stage of a company coming ahead of us," though management has not signaled M&A intent. Potential targets include Immatics, with a $1.3 billion market cap and an existing collaboration; Arbutus Biopharma, at $957.6 million, whose acquisition would extinguish $1.3 billion in contingent LNP patent exposure; Intellia Therapeutics, at $1.9 billion, with Phase 3 lonvo-z showing an 87% reduction in hereditary angioedema attacks; and Editas Medicine, at $442.3 million, offering cardiometabolic pipeline access.
MRNA · Capital · Positive Stock surge strengthens acquisition currency and balance sheet, enabling potential M&A.
ABUS · Capital · Positive Acquisition would extinguish $1.3 billion in contingent LNP patent exposure.
IMTX · Capital · Positive Existing collaboration and $1.3 billion market cap make it a likely acquisition target.
NTLA · Technology · Positive Phase 3 lonvo-z shows 87% reduction in hereditary angioedema attacks, enhancing value.
EDIT · Capital · Positive Offers cardiometabolic pipeline access, making it a strategic acquisition target.